Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the closing of its initial public offering of 6,762,000 shares of common stock at an initial public offering price of $17.00 per share. Akebia Therapeutics Inc (NASDAQ:AKBA) shares after opening at $21.16 moved to $22.31 on last trade day and at the end of the day closed at $19.15. Company price to cash ratio in past twelve months was calculated as 11.35. Akebia Therapeutics Inc (NASDAQ:AKBA) showed a negative weekly performance of -1.14%.
Celladon Corp (NASDAQ:CLDN) posted its quarterly earnings results on Monday. The company reported ($7.77) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.47) by $7.30,Analyst Ratings Network.com reports. Celladon Corp (NASDAQ:CLDN) shares fell -12.38% in last trading session and ended the day on $9.70. Celladon Corp (NASDAQ:CLDN) return on equity ratio is recorded as 83.40% and its return on assets is -105.30%.
Onconova Therapeutics, Inc. (NASDAQ:ONTX) presented at the Cowen and Company 34th Annual Health Care Conference in Boston, MA. Onconova Therapeutics Inc (NASDAQ:ONTX) shares moved down -2.10% in last trading session and was closed at $6.06 while trading in range of $5.92 – $6.19 – Onconova Therapeutics Inc (NASDAQ:ONTX) year to date (YTD) performance is -47.21%.
Dicerna Pharmaceuticals (NASDAQ:DRNA) announced its earnings results on Thursday. The company reported ($0.20) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.62) by $0.42, Stock Ratings Networkreports. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) weekly performance is -23.23%. On last trading day company shares ended up $23.50. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) distance from 50-day simple moving average (SMA50) is -34.45%. Analysts mean target price for the company is $47.33.
Leave a Reply